AMENDMENT NO. 1 TO CO-DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • May 4th, 2023 • Alector, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”) is effective as of February 13, 2023 (the “Amendment Effective Date”) by and between Alector, Inc., a Delaware corporation (“Licensor”), and AbbVie Biotechnology Ltd. (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
